Saruparib (AZD5305) plus Camizestrant compared with CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

Trial Identifier: D9722C00001
Sponsor: AstraZeneca
Start Date: April 2024
Primary Completion Date: March 2029
Study Completion Date: July 2030
Condition: Breast Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CA Toronto, CA, M4N 3M5
CA, ON Toronto, ON, CA, M5G 2M9
CA, QC Montreal, QC, CA, H3T 1E2
CA, Quebec Montréal, Quebec, CA, H2X 0A9
CA, SK Saskatoon, SK, CA, S7N 4H4